83440-03-3 Usage
Description
N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE, also known as 2-Nicotinamidoethyl acetate, is a pinacidil analogue of nicorandil, which is a potassium channel opener and nitric oxide donor. It has the ability to inhibit the release of TNFα from lymphocyte cell lines and peripheral blood lymphocytes.
Uses
Used in Pharmaceutical Industry:
N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE is used as a pharmaceutical agent for its ability to inhibit the release of TNFα from lymphocyte cell lines and peripheral blood lymphocytes. This makes it a potential candidate for the treatment of inflammatory and immune-related conditions.
Used in Cardiovascular Applications:
As a potassium channel opener and nitric oxide donor, N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE can be used in the treatment of cardiovascular diseases, such as angina pectoris, by improving blood flow and reducing the workload on the heart.
Used in Drug Delivery Systems:
N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE can be incorporated into drug delivery systems to enhance its therapeutic efficacy and bioavailability, making it a promising candidate for the development of novel pharmaceutical formulations.
Biological Activity
Analog of nicorandil . A nitrate-free coronary vasodilator; activates K + channels.
Check Digit Verification of cas no
The CAS Registry Mumber 83440-03-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,4,4 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 83440-03:
(7*8)+(6*3)+(5*4)+(4*4)+(3*0)+(2*0)+(1*3)=113
113 % 10 = 3
So 83440-03-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O3/c1-8(13)15-6-5-12-10(14)9-3-2-4-11-7-9/h2-4,7H,5-6H2,1H3,(H,12,14)
83440-03-3Relevant articles and documents
NOVEL DRUGS FOR DEMENTIA
-
Example 2, (2008/06/13)
The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors are effective for treating dementia, Alzheimer's disease and vascular dementia. Targeting the brain or central nervous system offers significant advantages in treating these conditions and diseases. A preferred CDS prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety.
